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In this issue of Neuron, Beppu et al. (2014) demonstrate that glial acidification during ischemia contributes to
neurotoxicity. Using a suite of in vivo optogenetic tools, the authors are able to exacerbate or attenuate
neuronal damage during ischemia with glial acidification or alkalization, respectively.Ischemic stroke is the second leading
cause of death and disability in humans
worldwide (Di Carlo, 2009), yet we still
understand remarkably little about the
mechanisms that perpetuate neuronal
toxicity during these events. Ischemic
episodes occur due to an interruption
of blood supply either focally (artery
blockage) or globally (cardiac arrest) and
result in oxygen and glucose deprivation
to the brain. The downstream conse-
quences of the absence of these essential
metabolic components are severe, with
neuronal death occurring in as little as
5 min. Despite the prevalence and severe
consequences of brain ischemia, there
are currently few pharmacological inter-
ventions capable of providing signif-
icant neuroprotection during a stroke.
This problem has motivated significant
research into the cellular mechanisms
that underlie ischemic brain damage in
hopes of revealing new therapeutic
avenues to address ischemic injury.
The best-understood mechanism of
neuronal death after ischemia is known
as ‘‘glutamate excitoxicity,’’ a term initially
coined based on the observation that
subcutaneous glutamate injections in
mice produce intracranial brain lesions
(Olney, 1969). Glutamate is themost prev-
alent neurotransmitter in the brain and
acts on a variety of synaptic receptors
in order to induce excitatory neuronal
depolarization. Despite its relative abun-
dance in the extracellular milieu of
the brain, glutamate is toxic at high
concentrations—a perilously thin margin
between physiology and toxicity. Gluta-
mate toxicity stems from the fact that
neuronal glutamate receptors allow cal-
cium ions to flow into the cell when acti-
vated by extracellular glutamate. Calciuminflux is required for normal synaptic
transmission and cellular signaling, but
the excess glutamate released during
ischemic injury results in intracellular
Ca2+ concentrations that far exceed
physiologic levels. At elevated concentra-
tions, excess Ca2+ results in the overacti-
vation of deleterious enzymes and
signaling processes that impair neuronal
function or initiate cell-death pathways
(Szydlowska and Tymianski, 2010).
While a large body of literature con-
tinues to investigate the specific mecha-
nisms implicated in the propagation of
excitotoxic signaling, a fundamental
question remains debated regarding the
cellular source of glutamate and its mech-
anism of release during ischemia. In this
issue of Neuron, elegant work by Beppu
et al. (2014) suggests that glial acidosis
after ischemia may act as a trigger for
ensuing neurotoxicity. Furthermore, the
authors provide evidence that interven-
tions to alkalize glia during ischemic
episodes are capable of attenuating
neuronal injury.
Astrocytes, the most abundant popula-
tion of nonneuronal cells in the brain, are
first responders to ischemic stress.
Furthermore, astrocytes have diverse
and significant roles in glutamatergic
signaling. For example, astrocytic gluta-
mate transporters are the primary control-
lers of ambient extracellular glutamate.
These qualities suggest that they may
play an integral role in the glutamate-
dependent excitotoxicity that accom-
panies ischemia. After ischemic injury,
oxygen and glucose deprivation cause
astrocytes to anaerobically metabolize
stored glycogen, thus producing signifi-
cant intracellular acidosis as a conse-
quence of accumulating lactate concen-Neuron 81trations. Beppu et al. (2014) asked
whether this glial acidosis might
contribute to ischemia-induced neuronal
toxicity in the brain. In order to address
this question they first loaded acute cere-
bellar slices with a pH-sensitive fluores-
cent dye and exposed the cells to oxygen
and glucose deprivation (OGD). After
OGD, Beppu et al. (2014) observed quick
acidification of the Bergmann glia (a
specialized subtype of astrocytes in the
cerebellum). When paired with the obser-
vation that astrocytes play pivotal roles in
neuronal survival and glutamate homeo-
stasis, these initial results suggested that
a dip in glial pH after OGD may serve as
a trigger for subsequent neurotoxicity.
Within minutes after OGD onset,
Purkinje cell neurons in the cerebellum
exhibit an inward excitatory current that
results from accumulating extracellular
glutamate. This deleterious depolarization
is almost entirely blocked with glutamate
receptor blockers and is unaffected by
the blockade of Na+ channels with tetro-
dotoxin (TTX), demonstrating that the
increasing inward current is indeed a
result of elevated extracellular glutamate
levels and not merely a consequence of
excess neuronal activity. Beppu et al.
(2014) used whole-cell patch-clamp re-
cordings in Purkinje cells to monitor this
OGD-evoked excitotoxic drive during
various experimental conditions to quan-
tify the significance of the excitotoxic phe-
nomenon. To bypass the OGD process
and directly acidify glial cells during phys-
iologically normal conditions, Beppu et al.
(2014) utilized the optogenetic tool chan-
nelrhodopsin 2 (ChR2), a light-sensitive
cation channel. Although ChR2 has been
extensively used in the neuroscience field
as a tool to temporally control neuronal, January 22, 2014 ª2014 Elsevier Inc. 221
Figure 1. A Model for Ischemia-Induced Excitotoxicity
Without a steady blood supply, oxygen, glucose, and ATP levels decline quickly in the ischemic region. As
a result, lactate begins to accumulate in astrocytes, acidifying the intracellular space. Glial acidification is
correlated with neuronal cell death, and alkalization is capable of attenuating the full neurotoxic effects.
Whether a mechanism for glial glutamate release exists in response to declining cytoplasmic pH remains
to be elucidated. The absence of ATP prevents the energy-dependent maintenance of normal ionic gra-
dients. Consequently, glutamate transporters that are typically responsible for clearing extracellular gluta-
mate begin to run in reverse and expel glutamate from astrocytes and neurons. Increased extracellular
glutamate levels activate glutamate receptors on neurons, which then leads to the toxic influx of calcium.
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Previewsmembrane depolarization, this channel
has increased permeability to H+ ions
than it does to Na+ (Nagel et al., 2003)
and can be essentially considered an op-
togenetic pH manipulator. Thus, the au-
thors attempted to utilize ChR2 as a
mechanism of inducing glial acidification
in the absence of OGD. Beppu et al.
(2014) transgenically expressed ChR2
exclusively in glia and observed intracel-
lular glial acidification quickly after light
activation of the channels. In the absence
of OGD, this ChR2-mediated glial acidifi-
cation produced the characteristic inward
excitatory current in surrounding Purkinje
cells, suggesting that glial acidification
plays a causal role in the induction of the
Purkinje cell excitotoxic drive.222 Neuron 81, January 22, 2014 ª2014 ElseSince glial acidosis contributes to
glutamatergic excitotoxicity during OGD,
Beppu et al. (2014) next wondered
whether glial alkalization could suppress
OGD neurotoxicity. In order to address
this question, the authors utilized a
transgenic mouse that expresses the
light-activated outward proton pump
archaerhodopsin (ArchT) under an astro-
cyte-specific promoter. Experiments
with the pH-sensitive indicator confirmed
that ArchT stimulation potently and spe-
cifically alkalized glial cells. Remarkably,
when Beppu et al. (2014) stimulated
ArchT during OGD conditions, the gluta-
mate-mediated Purkinje cell inward
current was significantly attenuated. In
fact, the inward current dissipated tovier Inc.nearly the same level as observed during
pharmacologic antagonization of the
glutamate receptors.
In a final experiment, Beppu et al. (2014)
addressed whether in vivo ArchT activa-
tion is neuroprotective during an ischemic
event as predicted from their previous
slice culture experiments. The authors
induced an ischemic stroke with the
commonly used photosensitive dye rose
bengal, which causes thrombosis when
focally excited with an optic fiber. Those
animals lacking ArchT activation ex-
hibited severe neuronal degeneration at
the ischemic injury site, but the cohort
receiving ArchT-mediated glial alkaliza-
tion demonstrated significantly reduced
infarct sizes. This is remarkable in vivo
proof-of-principal evidence that strongly
implicates the glial contribution to neuro-
toxicity following the onset of ischemia.
Figure 1 illustrates a summary model of
the cellular and molecular events that
involve neuroglial interactions during
ischemia.
Though the elegant experiments
performed by Beppu et al. (2014) demon-
strate an important role of glial acidifica-
tion during ischemia, several questions
remain regarding the cellular source of
glutamate release during OGD. The
authors reach the provocative conclusion
that glial acidification is directly upstream
of glial glutamate release during ischemia.
The mechanism of the proposed glial
glutamate release, however, remains a
mystery. To date, there is dearth of
evidence that astrocytes contain the
machinery required to release glutamate
under physiologic conditions. Astrocytes
lack the transport proteins required for
vesicular glutamate release, and export
of cytoplasmic glutamate seems unlikely
considering the high quantity of astrocytic
glutaminase that constantly degrades
cytoplasmic glutamate. Overall, there is
sparse data that under physiologic condi-
tions glutamate concentrations accumu-
late sufficiently in astrocytes for glial
glutamate release to be a significant
contributor to rising extracellular concen-
trations of glutamate. Although Beppu
et al. (2014) correlated glial acidification
with neural excitatory current, this is an
indirect observation that is not conclusive
of astrocytic release of glutamate.
If ischemic glutamate release does
not originate from astrocytes, what other
Neuron
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nomenon? One particularly pivotal event
during brain ischemia is the inhibition of
the Na+-K+ ATPase upon loss of cellular
ATP, which decreases to 0%–25% of
normal levels (Lipton, 1999). Inhibition of
the Na+-K+ ATPase quickly results in a
profound loss of intra- and extracellular
ionic gradients. These gradients are
essential to the function of glial and
neuronal glutamate transporters. Under
physiological conditions, the extracellular
concentration of glutamate is carefully
controlled by a family of high-affinity,
Na+-dependent glutamate transporters,
which couple the energetically unfavor-
able transport of glutamate with the ener-
getically favorable cotransport of Na+, K+,
and H+ down their respective electro-
chemical gradients. Under normal physio-
logic conditions, glutamate transporters
are responsible for clearing synaptically
released glutamate and maintaining the
ambient glutamate concentration at sub-
threshold levels. During brain ischemia,
the sudden ATP depletion and subse-
quent disruption of normal ion gradients
can cause glutamate transporters to run
in reverse, essentially expelling intracel-
lular glutamate into the extracellular
space. Previous in vitro and in vivo studies
using glutamate transporter antagonists
suggested that extracellular glutamate
accumulation after ischemia is largely
due to the reversal of these transporters
in both neurons and astrocytes (Phillis
et al., 2000; Rossi et al., 2000).
It is possible to reconcile older obser-
vations about glutamate transporter
reversal with glial glutamate release dur-
ing ischemic events. To address this sce-
nario, several issues need to be resolved.
First, ischemia-specific mechanisms of
glial glutamate release—typically absentunder physiologic conditions—need to
be identified. For example, it is possible
that glial glutamate concentrations
rise significantly during ischemia, thus
providing a substantial glutamate supply
for export to the extracellular milieu.
Next, the mechanism of how glutamate
escapes from astrocytes in response to
decreasing pH must be elucidated.
Neuronal expression of the pH-sensitive
neutral amino acid exchanger ASCT1
has been suggested to play a role in the
extracellular glutamate increase caused
by ischemia (Weiss et al., 2005), but astro-
cytes express ASCT1 at even higher
levels (S.A.S., unpublished data). This
transporter is therefore a strong candi-
date to be involved in the increase
in extracellular glutamate levels upon
astrocyte acidification. Future studies
of ischemic injury in ASCT1-deficient
mice could help to implicate these recep-
tors if they are truly involved in such a
mechanism.
The interest in the events that precipi-
tate neuronal toxicity after ischemia
stems from their potential as therapeutic
targets. Over the past several decades,
over one thousand clinical trials (O’Collins
et al., 2006), many of which involved an-
tagonists of glutamate receptor signaling,
have failed in humans despite extremely
promising histologic results in animals
(Muir, 2006). Due to their significant side
effects and lack of clinical efficacy,
searching for therapeutics that antago-
nize glutamate receptor activation may
have reached an impasse; instead, new
mechanisms that precipitate neurotox-
icity may provide a more fruitful avenue
for therapeutic success. Accordingly,
this work by Beppu et al. (2014) opens
novel opportunities to consider small mol-
ecules that could ameliorate the effects ofNeuron 81neurotoxicity during ischemia. Though
they would have to be administered
immediately after an ischemic event and
delivery to a nonperfused brain region
proves new obstacles, drugs that could
prevent glial acidification may potently
attenuate detrimental neuronal death.
Especially when one considers the global
epidemiology of stroke, any step forward
in clarifying the mechanisms that propa-
gate neuronal toxicity offers immense
potential to impact worldwide morbidity.
The work presented here by Beppu et al.
(2014) provides an outstanding example
of such a mechanistic leap—one that pro-
pels us ever closer to new therapies and
interventions for such a prevalent and
devastating condition.
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